(Q33395721)

26 July 2017

A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer (English)

1 reference

26 July 2017

1 reference

1 reference

H Iwase

1

1 reference

26 July 2017

M Shimada

2

1 reference

26 July 2017

T Tsuzuki

3

1 reference

26 July 2017

K Ina

4

1 reference

26 July 2017

M Sugihara

5

1 reference

26 July 2017

J Haruta

6

1 reference

26 July 2017

M Shinoda

7

1 reference

26 July 2017

T Kumada

8

1 reference

26 July 2017

H Goto

9

1 reference

26 July 2017

language of work or name

1 reference

10 June 2011

1 reference

26 July 2017

1 reference

26 July 2017

80

1 reference

26 July 2017

1-2

1 reference

26 July 2017

76-83

1 reference

Global cancer statistics, 2002

26 July 2017

1 reference

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

21 January 2018

1 reference

Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer

21 January 2018

1 reference

Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).

21 January 2018

1 reference

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 960

21 January 2018

1 reference

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

21 January 2018

1 reference

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

21 January 2018

1 reference

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

21 January 2018

1 reference

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

21 January 2018

1 reference

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

New perspectives in the treatment of advanced or metastatic gastric cancer

21 January 2018

1 reference

Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions

21 January 2018

1 reference

Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer.

21 January 2018

1 reference

Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer

21 January 2018

1 reference

24-hour infusion of cis-platinum in head and neck cancers

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000328746

1 reference

26 July 2017

1 reference